Nachrichten und Videos - ACTINIUM PHARMACEUTICALS - Seite 2

SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data PR Newswire NEW YORK, June 26, 2023 - SNMMI Henry N. Wagner, Jr., Abstract of the Year award represents top selection out of more than 1,500 abstracts accepted for presentation NEW YORK , June 26, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM, 'Actinium'), a leader in the development of targeted radiotherapies, today announced that the Society of Nuclear Medicine and...

Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting PR Newswire NEW YORK, June 23, 2023 NEW YORK , June 23, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details the six abstracts accepted for oral and poster presentation at the upcoming Society for Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting,...

Actinium Pharma to Present at the Maxim Healthcare Virtual Conference PR Newswire NEW YORK, June 16, 2023 NEW YORK , June 16, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company will participate in a fireside chat at the Maxim Healthcare Virtual Conference on Wednesday, June 21, 2023 at 12:30 PM EST . This conference will be webcast live on M-Vest. Sign up...

Actinium Pharma to Present at the TD Cowen Radiopharmaceutical Innovation Summit PR Newswire NEW YORK, June 14, 2023 NEW YORK , June 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company will participate in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023 at 1:30 PM EST . The live webcast of the presentation...

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress PR Newswire NEW YORK, June 12, 2023 SIERRA results demonstrate unprecedented bone marrow transplant access and outcomes with Iomab-B BLA filing for Iomab-B expected by year end 2023 based on positive pivotal Phase 3 SIERRA results NEW YORK , June 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of...

Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes PR Newswire NEW YORK, June 7, 2023 NEW YORK , June 7, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be added as a member of the small-cap Russell 2000® and all-cap Russell 3000® Indexes as part of the 2023 Russell indexes reconstitution, according to a preliminary list of additions...

Actinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Solid Cancers PR Newswire NEW YORK, May 22, 2023 Abstracts highlight data pertaining to both Iomab-B and Actimab-A clinical results including the SIERRA Phase 3 trial, dosimetry and machine learning applications for personalized radiotherapy dosing and novel radiotherapy discovery NEW YORK , May 22,...

Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA) PR Newswire NEW YORK, May 11, 2023 NEW YORK , May 11, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming European Hematology Association 2023 Congress (EHA),...

Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day PR Newswire NEW YORK, May 10, 2023 NEW YORK , May 10, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in 1x1 meetings and deliver a corporate presentation on Monday, May 15, 2023 at 3:20 PM EST at the Guggenheim Healthcare Talks...

Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers with Ease and Without Increasing Radiation Exposure Risks to Treating Nursing Staff in the Pivotal Phase 3 SIERRA Trial at the 48th Annual Oncology Nursing Society (ONS) Congress PR Newswire NEW YORK, April 28, 2023 - 24 leading bone marrow transplant (BMT) centers that perform over 30% of transplants in the U.S. participated in the SIERRA trial that enrolled patients with active relapsed or...

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting PR Newswire NEW YORK, April 27, 2023 - EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. - Iomab-B enabled unprecedented 100% bone marrow...

Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting PR Newswire NEW YORK, April 19, 2023 - Highly significant (p<0.0001) reduction in tumor volume in ovarian cancer model when using HER3-ARC conjugated to either Actinium-225 or Lutetium-177 compared to bevacizumab (Avastin) - HER3 is expressed at high levels within multiple solid tumors and has been linked to poor...

Actinium Presents Data Demonstrating Actimab-A's Potential Use Against Solid Tumors by Selectively Depleting Immunosuppressive MDSCs, a Key Component of the Tumor Microenvironment, at the AACR Annual Meeting PR Newswire NEW YORK, April 19, 2023 - Actimab-A displayed robust MDSC depletion at statistically superior levels to other CD33-targeted therapeutics, including unconjugated Lintuzumab and Mylotarg ™ - Myeloid derived suppressor cells (MDSCs) are ubiquitous across multiple cancer...

Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones PR Newswire NEW YORK, April 3, 2023 - Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR with high statistical significance (p<0.0001) - On track to commence Early Access Program and file a BLA submission for Iomab-B in 2H:2023 - Actimab-A + CLAG-M demonstrated 59% 1-year and 32% 2-year...

Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting PR Newswire NEW YORK, March 16, 2023 - First ever data demonstrating the novel application of Actimab-A to enhance antitumor immune activity by depleting MDSCs, a population of highly immunosuppressive cells closely associated with poor clinical outcomes in cancer - New solid tumor program data including the first exploration of the effects of targeting HER3 with either alpha (225Ac)-...

Actinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference PR Newswire NEW YORK, March 15, 2023 NEW YORK , March 15, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in a virtual presentation at Oppenheimer's 33 rd Annual Healthcare Conference being held March 13-17, 2023 . The...

Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL Webinar PR Newswire NEW YORK, Feb. 27, 2023 - KOL webinar on Tuesday, February 28, 2023 , at 8 a.m. EST - Actinium intends to file a BLA for Iomab-B in 2H:2023 following positive SIERRA trial results - Actinium reiterates current cash and cash equivalents of approximately $100 million are projected to fund operations through 2025 NEW YORK , Feb. 27, 2023...

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia PR Newswire NEW YORK, Feb. 18, 2023 - Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm - In patients achieving 6-month dCR with...

Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023 PR Newswire NEW YORK, Feb. 14, 2023 - Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023 , to feature Iomab-B SIERRA Pivotal Trial results - Investor call at 6:00 PM EST on Saturday, February 18, 2023 , to highlight full results from the Phase 3 SIERRA...

Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies PR Newswire NEW YORK, Feb. 6, 2023 - National Cancer Institute will sponsor and oversee clinical trials of Actimab-A under the terms of the Cooperative Research and Development Agreement - Collaboration will provide Actimab-A and other necessary support to...